PTC Therapeutics (PTCT)
(Delayed Data from NSDQ)
$31.73 USD
+0.80 (2.59%)
Updated Jul 8, 2024 04:00 PM ET
After-Market: $31.74 +0.01 (0.03%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth F Momentum C VGM
Price, Consensus and EPS Surprise
PTCT 31.73 +0.80(2.59%)
Will PTCT be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for PTCT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for PTCT
PTC Therapeutics (PTCT) Down on Negative CHMP Opinion on DMD Drug
PTC Therapeutics (PTCT) Soars 9.7%: Is Further Upside Left in the Stock?
PTCT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Pfizer (PFE) Phase III DMD Gene Therapy Study Misses Goal
The Zacks Analyst Blog Highlights Biogen, Ionis Pharmaceuticals, GSK, PTC Therapeutics and Larimar Therapeutics
Biotech Stock Roundup: BIIB's Acquisition, PTCT, LRMR Gain on Updates & More News
Other News for PTCT
Nike, Kura Sushi fall; Infinera, Protagonist Therapeutics rise, Friday, 6/28/2024
Sell Rating on PTC Therapeutics Amid Persistent Regulatory Hurdles for Translarna
Buy Rating for PTC Therapeutics: Translarna’s Continued EU Market Presence and Global Expansion Potential
Buy Rating on PTC Therapeutics: Market Overreaction and Opportunity Amidst CHMP Review
Nike, Accolade And Other Big Stocks Moving Lower In Friday's Pre-Market Session